MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,014K
Net Income
-$5,192K
Net Profit Margin
-512.03%
EPS
-$0.03
Unit: Thousand (K) dollars
Revenue Breakdown
License
Collaboration And Contracts
Non Cash Royalty
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
1,014
179,126
1,051
529
Research and development
2,898
4,120
5,006
5,778
General and administrative
3,867
5,889
3,689
3,044
Change in fair value of contingent consideration
213
209
-2,657
268
Restructuring costs
0
0
303
98
Total operating expenses
6,978
10,218
6,341
9,188
(loss) income from operations
-5,964
168,908
-5,290
-8,659
Interest income
842
815
877
952
Gain on sale of property and equipment
-
-
674
-
Interest expense
18
17
18
23
Foreign exchange (loss) gain
-3
-11
1
-12
Total other income
821
787
1,534
917
Net (loss) income
-5,143
169,695
-3,756
-7,742
Unrealized gain on available-for-sale securities
-
-
31
-
Unrealized loss on available-for-sale securities
-49
-97
-
58
Comprehensive (loss) income
-5,192
169,598
-3,725
-7,684
Basic EPS
-0.03
0.88
-0.019
-0.04
Diluted EPS
-0.03
0.87
-0.019
-0.04
Basic Average Shares
197,470,724
193,768,641
192,361,083
191,778,950
Diluted Average Shares
197,470,724
195,214,067
191,512,632
191,778,950
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive (loss) income
-$5,192K
(-307.51%↓ Y/Y)
Interest income
$842K
(-19.19%↓ Y/Y)
Net (loss) income
-$5,143K
(-303.84%↓ Y/Y)
Unrealized loss on
available-for-sale securities
-$49K
(-133.33%↓ Y/Y)
Total other income
$821K
(-20.68%↓ Y/Y)
License
$632K
Collaboration And Contracts
$202K
Non Cash Royalty
$180K
Interest expense
$18K
(-35.71%↓ Y/Y)
Foreign exchange (loss)
gain
-$3K
(-114.29%↓ Y/Y)
(loss) income from
operations
-$5,964K
(-500.81%↓ Y/Y)
Revenues
$1,014K
(-90.56%↓ Y/Y)
Total operating
expenses
$6,978K
(-24.57%↓ Y/Y)
General and
administrative
$3,867K
(16.20%↑ Y/Y)
Research and development
$2,898K
(-47.29%↓ Y/Y)
Change in fair value of
contingent consideration
$213K
(-18.08%↓ Y/Y)
Buy us a coffee
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)